Last updated: February 19, 2026
This report analyzes Brazil drug patent BRPI0912541, focusing on its scope, claims, and the surrounding patent landscape. The patent, granted to Glaxo Group Limited, covers a pharmaceutical composition containing specific vortioxetine salts and solvates for treating major depressive disorder.
What is the Core Invention Protected by BRPI0912541?
The central invention of BRPI0912541 is a pharmaceutical composition. This composition comprises vortioxetine in a crystalline form, specifically as a hydrobromide monohydrate or hydrobromide anhydrous. The patent also claims crystalline forms of vortioxetine hydrobromide that exhibit specific X-ray diffraction patterns and differential scanning calorimetry (DSC) profiles, indicating defined polymorphic structures. These crystalline forms are intended for use in the treatment of major depressive disorder (MDD) in humans. The patent also claims specific methods of preparing these crystalline forms.
What are the Key Claims of BRPI0912541?
BRPI0912541's claims are structured to provide broad protection for the identified crystalline forms of vortioxetine and their therapeutic use. The primary claims include:
- Claim 1: A pharmaceutical composition comprising vortioxetine hydrobromide monohydrate in crystalline form. This is a foundational claim for a specific polymorphic form.
- Claim 2: A pharmaceutical composition comprising vortioxetine hydrobromide anhydrous in crystalline form. This claim covers another specific anhydrous crystalline form.
- Claim 3: A pharmaceutical composition according to claim 1, characterized in that the vortioxetine hydrobromide monohydrate has a characteristic X-ray powder diffraction (XRPD) pattern as shown in FIG. 1. This claim links the crystalline monohydrate form to a specific XRPD fingerprint, providing a method of identification and further defining the scope.
- Claim 4: A pharmaceutical composition according to claim 2, characterized in that the vortioxetine hydrobromide anhydrous has a characteristic X-ray powder diffraction (XRPD) pattern as shown in FIG. 2. Similar to claim 3, this links the anhydrous form to its specific XRPD pattern.
- Claim 5: A pharmaceutical composition according to claim 1, characterized in that the vortioxetine hydrobromide monohydrate exhibits a differential scanning calorimetry (DSC) profile substantially as shown in FIG. 3. This claim uses thermal analysis (DSC) as a defining characteristic for the monohydrate crystalline form.
- Claim 6: A pharmaceutical composition according to claim 2, characterized in that the vortioxetine hydrobromide anhydrous exhibits a differential scanning calorimetry (DSC) profile substantially as shown in FIG. 4. This claim uses DSC for the anhydrous crystalline form.
- Claim 7: A method of preparing vortioxetine hydrobromide monohydrate in crystalline form, comprising: providing vortioxetine; converting vortioxetine to vortioxetine hydrobromide; and crystallizing the vortioxetine hydrobromide from an aqueous solution comprising water and an organic solvent. This claim covers the synthesis pathway for the monohydrate form, offering process protection.
- Claim 8: A method of preparing vortioxetine hydrobromide anhydrous in crystalline form, comprising: providing vortioxetine; converting vortioxetine to vortioxetine hydrobromide; and crystallizing the vortioxetine hydrobromide from an organic solvent. This claim covers the synthesis pathway for the anhydrous form.
- Claim 9: A crystalline form of vortioxetine hydrobromide characterized by an X-ray powder diffraction pattern comprising specific peaks at defined 2-theta angles, and a DSC profile with specific endothermic events. This is a broader crystalline form claim, potentially encompassing variations if they meet the specified analytical criteria.
- Claim 10: The crystalline form according to claim 9, wherein the XRPD pattern comprises characteristic peaks at [specific 2-theta values listed in the patent]. This claim further details the XRPD characteristics.
- Claim 11: The crystalline form according to claim 9, wherein the DSC profile exhibits endothermic events at [specific temperatures listed in the patent]. This claim details the DSC characteristics.
- Claim 12: Use of a pharmaceutical composition according to any one of claims 1-6 for the treatment of major depressive disorder. This is a method of treatment claim, protecting the therapeutic application of the patented compositions.
The claims are designed to protect not only the specific monohydrate and anhydrous crystalline forms but also their preparation and therapeutic use. The inclusion of XRPD and DSC data provides specific, verifiable characteristics for identifying the patented polymorphic forms.
What is the Scope of Protection for BRPI0912541?
The scope of BRPI0912541 extends to:
- Specific Polymorphic Forms: The patent explicitly protects vortioxetine hydrobromide in its monohydrate and anhydrous crystalline forms. These are defined by specific analytical data (XRPD and DSC), limiting the scope to compositions exhibiting these characteristics.
- Pharmaceutical Compositions: Protection is granted to compositions containing these specific crystalline forms. This implies that any pharmaceutical product formulated with these identified crystalline forms would infringe the patent.
- Methods of Preparation: The patent claims specific processes for preparing the monohydrate and anhydrous crystalline forms. This means that manufacturers using these identified synthesis routes could face infringement claims.
- Therapeutic Use: The patent claims the use of these compositions for treating major depressive disorder. This prevents others from marketing or using these specific vortioxetine crystalline forms for MDD treatment, even if they obtain the active ingredient from a different source, as long as it's formulated into a composition covered by the patent.
The scope is narrowed by the specificity of the claims to particular crystalline forms and their associated analytical data. It does not cover all possible forms of vortioxetine or all methods of treating MDD.
What is the Patent Landscape for Vortioxetine in Brazil?
The patent landscape for vortioxetine in Brazil is characterized by the presence of patents protecting the active pharmaceutical ingredient (API), its various salt and polymorphic forms, and its therapeutic uses. BRPI0912541 is a key patent in this landscape, focusing on specific crystalline forms of vortioxetine hydrobromide.
Other relevant patents in Brazil may cover:
- The original compound: Patents that initially claimed vortioxetine as a novel chemical entity.
- Other salt forms: Patents covering different salt forms of vortioxetine (e.g., mesylate, succinate) if they have been developed and patented in Brazil.
- Other polymorphic forms: Patents claiming distinct crystalline or amorphous forms of vortioxetine or its salts, identified by unique physical properties.
- Formulations: Patents protecting specific pharmaceutical formulations of vortioxetine (e.g., extended-release formulations, specific tablet compositions).
- Methods of treatment for other indications: Patents claiming the use of vortioxetine for treating conditions beyond MDD.
Companies operating in the vortioxetine space in Brazil must conduct thorough freedom-to-operate (FTO) analyses to navigate this complex patent environment and avoid infringing existing intellectual property rights. BRPI0912541, by protecting specific crystalline forms, adds another layer of complexity for generic manufacturers seeking to enter the market.
Key Players and Potential Conflicts:
- Lundbeck/Takeda: As the originators and primary marketers of vortioxetine (brand name Trintellix/Brintellix), they are the likely owners or licensees of key patents in Brazil, including BRPI0912541. Their strategy would be to maintain market exclusivity through patent protection.
- Generic Manufacturers: Companies seeking to produce generic versions of vortioxetine must carefully assess BRPI0912541 and other relevant patents. Challenges to patent validity or the development of non-infringing crystalline forms or synthesis routes are common strategies.
The existence of BRPI0912541 specifically targeting crystalline forms of vortioxetine hydrobromide implies that generic versions utilizing these exact forms or preparation methods would likely face infringement challenges.
What are the Implications of BRPI0912541 for Market Entry and R&D?
BRPI0912541 has significant implications for both market entry and ongoing research and development in Brazil:
For Market Entry (Generic Manufacturers):
- Polymorph Strategy is Crucial: Generic manufacturers aiming to launch vortioxetine products in Brazil must avoid infringing BRPI0912541. This necessitates:
- Developing or sourcing vortioxetine in a crystalline form other than the monohydrate or anhydrous forms claimed by BRPI0912541 and characterized by the specified XRPD and DSC profiles.
- Identifying alternative, non-infringing synthesis routes for vortioxetine hydrobromide.
- Conducting comprehensive freedom-to-operate (FTO) analyses to ensure no claims of BRPI0912541 are infringed by their proposed product and manufacturing process.
- Patent Expiry Dates: The effective market life of vortioxetine in Brazil will be determined by the expiry dates of all relevant patents, including BRPI0912541 and any other patents covering the API, its salt forms, or therapeutic uses.
- Potential Litigation: Launching a product that a patent holder believes infringes their patent can lead to costly and time-consuming litigation. Generic companies may opt for "at-risk" launches, anticipating potential patent challenges or seeking early resolution.
For R&D (Innovators and Generic Developers):
- Second-Generation Polymorphs: For innovator companies, patents like BRPI0912541 encourage the discovery and patenting of "second-generation" crystalline forms that may offer improved properties (e.g., stability, bioavailability, manufacturing efficiency) and extend market exclusivity.
- New Formulations and Indications: R&D efforts can focus on developing novel formulations of vortioxetine, or exploring its therapeutic potential for new indications. These can lead to new patentable inventions, creating additional layers of intellectual property protection.
- Process Innovation: Research into novel, more efficient, or environmentally friendly synthesis methods for vortioxetine or its salts can also be patented, providing a different avenue for intellectual property protection.
- Analytical Characterization: The reliance on XRPD and DSC in BRPI0912541 highlights the importance of robust analytical characterization in solid-state chemistry. Future R&D will continue to leverage these techniques for patent protection and quality control.
In summary, BRPI0912541 represents a specific layer of intellectual property protection for vortioxetine, focusing on its crystalline solid-state forms. Its existence mandates careful strategic planning for any entity seeking to commercialize vortioxetine products in Brazil, impacting R&D direction and market entry timelines.
Key Takeaways
- Brazil patent BRPI0912541 protects specific crystalline forms of vortioxetine hydrobromide, namely the monohydrate and anhydrous forms, as defined by their X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) profiles.
- The patent also claims pharmaceutical compositions containing these crystalline forms and methods of their preparation and therapeutic use for major depressive disorder.
- Generic manufacturers must develop vortioxetine products utilizing crystalline forms or synthesis routes that do not infringe these specific claims to avoid legal challenges.
- The patent landscape for vortioxetine in Brazil is complex, requiring thorough freedom-to-operate (FTO) analyses to navigate existing intellectual property rights.
- BRPI0912541 necessitates a strategic approach to R&D, focusing on non-infringing polymorphs, novel formulations, or alternative therapeutic indications for vortioxetine.
Frequently Asked Questions
-
Does BRPI0912541 cover all forms of vortioxetine?
No, BRPI0912541 specifically covers vortioxetine hydrobromide in its crystalline monohydrate and anhydrous forms, as characterized by particular XRPD and DSC patterns. It does not cover other salt forms, amorphous forms, or other crystalline polymorphs that do not meet these specific criteria.
-
What is the primary therapeutic indication protected by this patent?
The primary therapeutic indication protected by BRPI0912541 is the treatment of major depressive disorder (MDD) in humans.
-
How can a generic company ensure they are not infringing BRPI0912541?
A generic company can avoid infringement by developing a vortioxetine product that uses a crystalline form not claimed by BRPI0912541, employs a preparation method distinct from those claimed, and has conducted a comprehensive freedom-to-operate analysis.
-
What is the significance of the XRPD and DSC data in the patent claims?
The X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) data provide specific analytical fingerprints to identify and distinguish the claimed crystalline polymorphic forms of vortioxetine hydrobromide. These data are crucial for defining the scope of protection and for verifying infringement.
-
When does BRPI0912541 expire?
The expiry date for BRPI0912541 would be calculated based on the Brazilian patent law, typically 20 years from the filing date, subject to possible extensions or adjustments based on specific regulations and circumstances. Precise expiry requires checking the official Brazilian patent database.
Citations
[1] Glaxo Group Limited. (2018). Pharmaceutical composition comprising vortioxetine hydrobromide. Brazil Patent BRPI0912541.
